MARKET

SELB

SELB

Selecta
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.110
+0.130
+4.36%
After Hours: 3.080 -0.03 -0.96% 17:40 05/07 EDT
OPEN
2.950
PREV CLOSE
2.980
HIGH
3.179
LOW
2.910
VOLUME
885.35K
TURNOVER
--
52 WEEK HIGH
5.70
52 WEEK LOW
1.470
MARKET CAP
352.03M
P/E (TTM)
-4.4975
1D
5D
1M
3M
1Y
5Y
Selecta Biosciences to Host Conference Call and Webcast to Discuss First Quarter 2021 Financial Results and Provide Business Update
Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR(TM) platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host a con...
GlobeNewswire · 2d ago
Is It Time to Buy These 3 Stocks?
It may be time to buy Twitter, Inc. (NYSE: TWTR), Selecta Biosciences, Inc. (NASDAQ: SELB), and FARO Technologies, Inc. (NASDAQ: FARO
Benzinga · 5d ago
INSIGHT-Spies, satellites, subpoenas: soy buyers play hardball with Brazilian farmers
reuters.com · 5d ago
Selecta Biosciences Stock Is Estimated To Be Possible Value Trap
GuruFocus News · 04/30 16:12
Canaccord Genuity Sticks to Its Buy Rating for Selecta Biosciences (SELB)
In a report released yesterday, John Newman from Canaccord Genuity maintained a Buy rating on Selecta Biosciences (SELB), with a price target of $13.00.
SmarterAnalyst · 04/30 10:18
65 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) jumped 33.1% to settle at $3.34 on Thursday as the company said it has been named as sponsor related to 4 SPACs.
Benzinga · 04/30 09:22
Selecta Biosciences Announces Three Presentations At Upcoming 24th Annual Meeting Of The American Society Of Gene & Cell Therapy May 11-14
Selecta Biosciences, Inc. (NASDAQ:SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today
Benzinga · 04/29 20:50
Selecta Biosciences Announces Three Presentations at the Upcoming 24th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
GlobeNewswire · 04/29 20:41
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SELB. Analyze the recent business situations of Selecta through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SELB stock price target is 8.00 with a high estimate of 13.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 134
Institutional Holdings: 53.11M
% Owned: 46.92%
Shares Outstanding: 113.19M
TypeInstitutionsShares
Increased
36
8.48M
New
26
3.27M
Decreased
23
15.03M
Sold Out
10
7.52M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Independent Director
Carrie Cox
President/Chief Executive Officer/Director
Carsten Brunn
Chief Financial Officer/Chief Accounting Officer
Bradford Dahms
Chief Operating Officer/Senior Vice President
Lloyd Johnston
Chief Scientific Officer
Takashi Kishimoto
Independent Director
Goran Ando
Independent Director
Timothy Barabe
Independent Director
Scott Myers
Independent Director
Aymeric Sallin
Independent Director
Timothy Springer
Independent Director
Patrick Zenner
No Data
About SELB
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company's lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

Webull offers kinds of Selecta Biosciences Inc stock information, including NASDAQ:SELB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SELB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SELB stock methods without spending real money on the virtual paper trading platform.